A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)

Inclusion Criteria: * Cytologically or histologically confirmed diagnosis of relapsed/refractory or newly diagnosed AML per WHO 2016 classification. * Phase 1a: AML that is relapsed/refractory or that is previously untreated in patients not considered suitable for intensive induction therapy. * Phase 1b: AML that is relapsed/refractory after prior treatment with a HMA-based regimen. * Phase 2: Previously untreated AML in patients who are not considered suitable candidates for intensive induction therapy. * Adequate renal and liver function. * Age ≥18 years. * Adequate performance status. Exclusion Criteria: * In Phase 1a and 1b, patients that have undergone prior allo-HSCT must be at least 3 months post-HSCT, without uncontrolled graft-versus-host disease (GVHD). For Phase 2, patients that have undergone prior allo-HSCT are excluded. * Patients with newly diagnosed AML with favorable risk cytogenetics such as t(8;21), inv(16), or t(16;16) as per the NCCN Guidelines Version 3, 2019 for AML. * Patients with acute promyelocytic leukemia (APL). * Prior treatment with any anti-CD47 or anti-SIRPalpha (signal regulatory protein alpha) agent. * Known active viral infections, including hepatitis B and C, human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS) related illness, or SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).